Member-only story

The Embarrassing Part about Big Pharma’s Dirty Little Secret

Jeffrey Goodman
11 min readSep 4, 2023

--

A good definition for the word “chutzpah” is “unmitigated gall.” Here’s a real-life example from a Big Pharma CEO.

Photo by freestocks on Unsplash

Related and recent articles

Has U.S. Healthcare Really Become a Mob Protection Racket?
My Health Insurance Company Asked for Feedback on My Specialist. I Blew My Top.
My Top 1% Friend Was Floored by the Cost of His Family’s Health Insurance
(Part 5 • Smart Man’s Disease) Six Behavioral Barriers That Prevent You from Changing the Status Quo
The Rule of 72 — A Shortcut That Makes Anyone Look Like a Math Genius
5 Things You Need to Know About U.S. Stock Buybacks

(Subscribe to receive email notifications when I post new articles.)

How often are we told that prescription drug prices in the U.S. must be expensive because “if pharmaceutical companies can’t charge high enough prices, they won’t be able to afford the R&D (research and development) costs necessary to develop all the new drugs that sooo benefit all of us Americans?”

Pretty often, right? I know I hear it all the time.

It’s fair to say that a large percentage of Americans have actually been trained by now to believe that line.

Turns out, however, that excuse is:

  • factually incorrect;
  • self-serving; and
  • what Big Pharma CEO grifters and swindlers say to justify squeezing as much money as they can out of sick people in the U.S.

And they squeeze the money out of them down to — and often beyond — their last dollar.

This article by Kat MediumThese Three Pills Cost $613 • We’re being raped by Big Pharma — is a great example of the “Big Pharma Squeeze” and lays the situation out perfectly from a consumer’s/patient’s point of view.

Photo by Matt Duncan on Unsplash

Here’s the roadmap for today:

  1. U.S. Representative Katie Porter

--

--

Jeffrey Goodman
Jeffrey Goodman

Written by Jeffrey Goodman

Navigating facts and numbers to help people. Strong opinions on climate change and healthcare. Objective, not neutral. MIT engineer, Wharton MBA.

Responses (9)

Write a response